A Clinical Trial to Find the Optimal Dose of BNT323 and BNT327 for Advanced Breast Cancer
Phase 1/2
380
about 4.1 years
18+
9 sites in CA, FL, GA +5
What this study is about
This trial is testing a combination treatment, BNT323 and BNT327, in people with advanced breast cancer. The goal is to find the best dose of this combination and see if it's safe and helpful.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BNT323
- 2.Take BNT327
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Occurrence of Treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs, Occurrence of dose interruption, reduction, and discontinuation due to TEAEs, Part 2 - Objective response rate (ORR)
Secondary: Part 1 - ORR, Part 2 - Disease control rate (DCR), Part 2 - Duration of response (DoR), Part 2 Cohort 1 only - Progression free survival (PFS)
Oncology